CT-388: Mechanism, Trials, and What the Data Actually Shows
CT-388 is a Phase 2 program from Roche/Carmot built around GLP-1/GIP. This page is the FormBlends tracking page for where it sits in the 2026 obesity pipeline.
Developer
Roche/Carmot
Mechanism
GLP-1/GIP
Stage
Phase 2
Tracked in
Dual agonists
Approval and timeline
Need the straight approval read on CT-388?
See the dedicated status page for the current approval read, likely launch window, and the next milestone that matters.
View CT-388 statusCompound facts for search and AI answers
What this CT-388 tracking page answers
Compound
CT-388 from Roche/Carmot
CT-388 is tracked in the dual agonists group.
Mechanism
GLP-1/GIP
Mechanism explains why this compound belongs in its pipeline bucket.
Current stage
Phase 2
This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials.
Evidence read
No mature public weight-loss signal pinned yet
CT-388 should be read as an evidence-tracking page, not as a patient access page. FormBlends has not pinned this page to a mature public weight-loss signal yet, so mechanism and development stage carry more weight than outcome claims. This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials. The next useful milestone is a clean human readout, regulatory update, or sponsor disclosure that changes the evidence base. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Clinical evidence snapshot
What the evidence can and cannot say about CT-388
CT-388 should be read as an evidence-tracking page, not as a patient access page. FormBlends has not pinned this page to a mature public weight-loss signal yet, so mechanism and development stage carry more weight than outcome claims. This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials. The next useful milestone is a clean human readout, regulatory update, or sponsor disclosure that changes the evidence base. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Decision path
Is CT-388 available now or watchlist only?
CT-388 should be interpreted through its current development stage, not through gray-market availability claims. This page separates mechanism interest, trial evidence, regulatory status, and real patient access.
- Compound
- CT-388
- Developer
- Roche/Carmot
- Stage
- Phase 2
- Mechanism
- Dual agonists
Step 1
Read the stage first
This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials.
Check statusStep 2
Separate evidence from access
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Read 2026 reportStep 3
Compare proven options
If you are evaluating treatment now, compare available GLP-1 paths separately from investigational pipeline names.
View current optionsFast answers
What is CT-388?
CT-388 is a phase 2 obesity or metabolic program from Roche/Carmot built around GLP-1/GIP.
Is CT-388 approved?
No. CT-388 is still a Phase 2 program. It belongs in the serious mid-stage watchlist, not in the approved-product bucket.
When could it matter?
2028 or later if the development path accelerates cleanly.
What CT-388 is
CT-388 is part of the dual agonists cluster in the FormBlends obesity-pipeline map. We track it because Roche/Carmot is using GLP-1/GIP as a bet on what comes after the first wave of blockbuster GLP-1 therapies.
Where it sits in the 2026 pipeline
This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials.
Dual agonists are still where a large share of the near-term obesity market is being shaped. This group includes both incremental challengers to today's GLP-1 leaders and some of the most commercially realistic next-wave products.
What FormBlends is watching next
For CT-388, the next useful signal is not just another headline. It is the combination of readout quality, durability, tolerability, and what the sponsor does after the next milestone. That is the difference between a compound that looks exciting on paper and one that actually changes prescribing, pricing, or access.
Access and regulatory reality
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
More dual agonists on FormBlends
Frequently asked questions
What is CT-388?
CT-388 is a Phase 2 obesity or metabolic compound from Roche/Carmot. FormBlends tracks it in the dual agonists group and follows it for trial progress, regulatory movement, and competitive impact.
How does CT-388 work?
CT-388 is being tracked as a GLP-1/GIP program. That mechanism is the main reason it sits inside the dual agonists bucket of the 2026 obesity pipeline.
Is CT-388 available now?
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Why is FormBlends tracking CT-388?
Dual agonists are still where a large share of the near-term obesity market is being shaped. This group includes both incremental challengers to today's GLP-1 leaders and some of the most commercially realistic next-wave products.